Ibrutinib

149 interactions 1 explained in plain English 563 cited references

Also sold as: Imbruvica Imbruvica®

About Ibrutinib

Ibrutinib is used: to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication, to treat people with chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood c… Read the full Ibrutinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mumps Virus Vaccine, Live Ensitrelvir Levoketoconazole Dengue Tetravalent Vaccine, Live Bacillus Of Calmette And Guerin Vaccine, Live Measles Virus Vaccine, Live

11 Contraindicated 129 Major 9 Moderate

All (149) Contraindicated (11) Major (129) Moderate (9)

Contraindicated

Ibrutinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ibrutinib Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Ibrutinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Ibrutinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Ibrutinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Ibrutinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Ibrutinib Relugolix Orgovyx Increased relugolix exposure Details Ibrutinib Apixaban Eliquis Increased risk of bleeding Details Ibrutinib Aspirin Acuprin® Increased risk of bleeding Details Ibrutinib Aspirin Rectal Aspirin Increased risk of bleeding Details Ibrutinib Anagrelide Agrylin Increased risk of bleeding Details Ibrutinib Clopidogrel Plavix Increased risk of bleeding Details Ibrutinib Cyclosporine Injection Atopica Increased ibrutinib exposure Details Ibrutinib Cyclosporine Ophthalmic Cequa Increased ibrutinib exposure Details Ibrutinib Dabigatran Pradaxa® Increased risk of bleeding Details Ibrutinib Dabigatran Etexilate Increased risk of bleeding Details Ibrutinib Dalteparin Injection Fragmin Increased risk of bleeding Details Ibrutinib Digoxin Cardoxin® Increased digoxin exposure Details Ibrutinib Dipyridamole Permole® Increased risk of bleeding Details Ibrutinib Edoxaban Savaysa Increased risk of bleeding Details Ibrutinib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Ibrutinib Enoxaparin Lovenox Increased risk of bleeding Details Ibrutinib Enoxaparin Injection Lovenox Increased risk of bleeding Details Ibrutinib Fondaparinux Arixtra Increased risk of bleeding Details Ibrutinib Fondaparinux Injection Arixtra Increased risk of bleeding Details Ibrutinib Heparin Increased risk of bleeding Details Ibrutinib Heparin Injection Lipo-Hepin® Increased risk of bleeding Details Ibrutinib Abciximab Increased risk of bleeding Details Ibrutinib Acenocoumarol Increased risk of bleeding Details Ibrutinib Adagrasib Krazati Increased CYP3A4 substrate exposure Details Ibrutinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Ibrutinib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Ibrutinib Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Ibrutinib Aprepitant Aponvie Increased ibrutinib exposure Details Ibrutinib Ardeparin Increased risk of bleeding Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.